It looks like activist fund Starboard Value is not impressed with the progress of Perrigo (PRGO) ever since the Dublin-based drugmaker spurned an April 2015 takeover offer from industry peer Mylan (MYL) . The activist fund -- which disclosed a roughly 4.6% in Perrigo Sunday -- told Perrigo's CEO John Hendrickson in a letter that since that spring Perrigo's "promises have been woefully unfulfilled." Starboard also noted that the Mylan offer would have created a current value of about $167 a share, that's roughly 88 percent higher from Perrigo's closing stock price Friday.
More from Video
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.